Brind.
  1. TD Cowen provided analyst estimates for US sales while the FDA continues to regulate drug approval in the US market.

TD Cowen downgraded Sarepta Therapeutics stock due to increased probability of drug withdrawal pending FDA approval.

1 report, 0 independent Updated Jun 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

TD Cowen downgraded Sarepta Therapeutics stock due to increased probability of drug withdrawal pending FDA approval.

Who's involved

What this event is mainly about
Sarepta TherapeuticsTD Cowen

Keep exploring

Part of

TD Cowen provided analyst estimates for US sales while the FDA continues to regulate drug approval in the US market. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet